These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 23148309

  • 1. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF.
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [Abstract] [Full Text] [Related]

  • 2. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
    Kristensen LE, Petersson IF, Geborek P, Jöud A, Saxne T, Jacobsson LT, Englund M.
    Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
    [Abstract] [Full Text] [Related]

  • 3. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, Perricone R, Chimenti S, Chimenti MS.
    Dermatology; 2012 Jul; 225(4):312-9. PubMed ID: 23295383
    [Abstract] [Full Text] [Related]

  • 5. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [Abstract] [Full Text] [Related]

  • 6. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [Abstract] [Full Text] [Related]

  • 7. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B, Fox KM, Watson C, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [Abstract] [Full Text] [Related]

  • 8. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
    Olofsson T, Petersson IF, Eriksson JK, Englund M, Nilsson JA, Geborek P, Jacobsson LTH, Askling J, Neovius M, ARTIS Study Group.
    Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
    [Abstract] [Full Text] [Related]

  • 9. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 10. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P.
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [Abstract] [Full Text] [Related]

  • 11. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.
    Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.
    Arthritis Care Res (Hoboken); 2014 Mar; 66(3):464-72. PubMed ID: 24022870
    [Abstract] [Full Text] [Related]

  • 13. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [Abstract] [Full Text] [Related]

  • 14. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 15. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.
    J Med Econ; 2013 Apr; 16(4):479-89. PubMed ID: 23339434
    [Abstract] [Full Text] [Related]

  • 16. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Apr; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 17. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis.
    Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J.
    Rheumatology (Oxford); 2008 Apr; 47(4):481-3. PubMed ID: 18281690
    [Abstract] [Full Text] [Related]

  • 18. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M, Wirthmüller U, Möller B, Villiger PM.
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE, Gülfe A, Saxne T, Geborek P.
    Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
    [Abstract] [Full Text] [Related]

  • 20. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P.
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1362-9. PubMed ID: 20506310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.